verapamil has been researched along with Dizzyness in 6 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In all patients combined, the incidence of constipation (13% vs 2%), dizziness (6% vs 2%), and back pain (3% vs 1%) was higher in patients treated with COER verapamil than with placebo." | 8.81 | Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. ( Anders, RJ; Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| " This verapamil formulation can be clinically titrated within a 180 to 540 mg dosing range, permitting effective once-daily administration for the treatment of chronic stable angina." | 6.68 | Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. ( Anders, RJ; Awan, NA; Bultas, J; Cutler, NR; Jhee, SS; Lahiri, A; Sramek, JJ; Woroszylska, M, 1995) |
| "In all patients combined, the incidence of constipation (13% vs 2%), dizziness (6% vs 2%), and back pain (3% vs 1%) was higher in patients treated with COER verapamil than with placebo." | 4.81 | Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. ( Anders, RJ; Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| " This verapamil formulation can be clinically titrated within a 180 to 540 mg dosing range, permitting effective once-daily administration for the treatment of chronic stable angina." | 2.68 | Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. ( Anders, RJ; Awan, NA; Bultas, J; Cutler, NR; Jhee, SS; Lahiri, A; Sramek, JJ; Woroszylska, M, 1995) |
| " Two patients with mild symptoms were rechallenged with a lower verapamil dosage (120 mg twice a day) and showed similar rises in CBZ concentration and recurrent neurotoxic symptoms." | 2.66 | Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. ( Brodie, MJ; Macphee, GJ; McInnes, GT; Thompson, GG, 1986) |
| "The mean pre-treatment Dizziness Handicap Inventory score was 57." | 1.56 | Pharmacotherapy failure and progression to botulinum toxin injection in vestibular migraine. ( Donaldson, L; Dornhoffer, JR; Liu, YF; Macias, D; Rizk, HG, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, YF | 1 |
| Macias, D | 1 |
| Donaldson, L | 1 |
| Dornhoffer, JR | 1 |
| Rizk, HG | 1 |
| Covinsky, JO | 1 |
| Hamburger, SC | 1 |
| Resnekov, L | 1 |
| Cutler, NR | 1 |
| Anders, RJ | 2 |
| Jhee, SS | 1 |
| Sramek, JJ | 1 |
| Awan, NA | 1 |
| Bultas, J | 1 |
| Lahiri, A | 1 |
| Woroszylska, M | 1 |
| White, WB | 1 |
| Johnson, MF | 1 |
| Elliott, WJ | 1 |
| Black, HR | 1 |
| Macphee, GJ | 1 |
| McInnes, GT | 1 |
| Thompson, GG | 1 |
| Brodie, MJ | 1 |
2 reviews available for verapamil and Dizzyness
| Article | Year |
|---|---|
Slow channel blockers.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Cons | 1983 |
Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Back Pain; Constipation; Delayed-Action Preparation | 2001 |
2 trials available for verapamil and Dizzyness
| Article | Year |
|---|---|
Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris.
Topics: Adult; Aged; Analysis of Variance; Angina Pectoris; Chronic Disease; Constipation; Delayed-Action Pr | 1995 |
Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction.
Topics: Adult; Carbamazepine; Clinical Trials as Topic; Dizziness; Double-Blind Method; Drug Synergism; Drug | 1986 |
2 other studies available for verapamil and Dizzyness
| Article | Year |
|---|---|
Pharmacotherapy failure and progression to botulinum toxin injection in vestibular migraine.
Topics: Adult; Aged; Aged, 80 and over; Botulinum Toxins; Dizziness; Female; Humans; Injections; Male; Middl | 2020 |
Calcium ion blocking drugs.
Topics: Administration, Oral; Bradycardia; Calcium Channel Blockers; Diltiazem; Dizziness; Headache; Heart D | 1982 |